Navigation Links
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter. In addition, Isis currently owns approximately 2% of the outstanding common stock of OncoGenex.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of OGX-011 for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...IS, Nov. 6 Recession in ...press sales for Allied Healthcare Products in the ... 30, 2009. ,, Sales declines pushed Allied into...rter was about $745,000, or negative 9 cents per s... about $208,000, or 3 cents per share. ,, Sale...
(Date:11/6/2009)..., Calif., Nov. 6 Kaiser Foundation...FHP/H), and their subsidiaries reported today a co...r the quarter ended September 30, 2009, compared t... Operating income in the third quarter was $336 mi...er of last year. Net non-operating income was $233...
(Date:11/6/2009)...TON, Nov. 6 America,s S...orking group of mid-market and smaller innovator p...about H.R. 3962, the "Affordable Health Care for A...ursday. These smaller companies fear that the cum...2 will hinder their efforts to bring new medicines...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 1Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 2 2416 8 million grant awarded to develop platelet recovery treatments 58550 1 2416 8 million grant awarded to develop platelet recovery treatments 58550 2Places to play but stranger danger fears keep inner city kids home 3A Study 58546 1
(Date:11/9/2009)... Only 5 percent of seniors have changed M...vings, better service and improved coverage among ...lment season nears , , Be...y 5 percent of seniors have changed their Medicare... (16 percent) report they are likely to or are con...
(Date:11/9/2009)... Nov. 9 HUYA Bioscience Internat...utical innovation, today announced a strategic par... Ocean University of China. The agreement is anoth...ablished with China,s leading research and develop...bal development and commercialization of novel bio...
(Date:11/9/2009)...l. -- Gifted young athletes are under increasing p... a new Loyola University Health System study of 51...lization increases the risk of injury. Researchers...s Association junior competition found that player...to withdraw from tournaments for medical reasons, ...
(Date:11/9/2009)...niversity study involving 2,453 women ages 18 to 6...alone or with a partner contributed to higher rati...al lubricants have long been recommended to women ...o reduce the risk of vaginal tearing, yet striking...se of lubricants or associated vaginal symptoms. ...
(Date:11/8/2009)..., Nov. 8 Jon O,Brien, p...wing statement about the passage of HR 3962: ,...can voters a lot about core values. We in the proc...eking to overcome the struggles ordinary Americans...many cannot afford basic healthcare or have to cho...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:Catholics for Choice Statement on Healthcare Reform Bill 2
...ash., March 30 Becoming the first long term care ...ee owned, Evergreen Healthcare and its affiliates ... from private ownership to being 100% owned by an ...ll have long, fulfilling careers with Evergreen He...
... CRME TSX: COM, , , VANCOUVER, March 30 /PRNews...RME / TSX: COM) today reported financial results f...ss specified otherwise, are expressed in Canadian ...nge rate was CAD$1.00=US$0.8210. , , Summary Fisc...
...Y, Pa., March 30 Air Products (NYSE: APD ) has ...manager, Global Liquid Bulk, Generated Gases, and ...ble for the worldwide leadership and management of...iness Services, where he led the company,s efforts...
... cells and the chemicals used to make bombs can fo...too small for conventional detection techniques. T...tion: a molecule that can magnify weak traces of "...rly Sackler School of Chemistry has engineered new...
...rch 30 A new study released today by the national...mocracy finds that medical devices for the heart h...hs, yet patients currently have no legal recourse ..., comes one day before dozens of patients living w...
..., March 30 , , (Logo: http://www.newscom.com/... David Gulian, President and CEO of InfoLogix; Ric...; and Gerry Bartley, Executive Vice President and ...views. , , Topics of expertise include: , , , ...
Other Medicine News:Health News:Evergreen Healthcare L.L.C. Announces 100% Employee Ownership 2Health News:Cardiome Reports 2008 Results 2Health News:Cardiome Reports 2008 Results 3Health News:Cardiome Reports 2008 Results 4Health News:Air Products Appoints John Marsland VP and GM of Global Liquid Bulk, Generated Gases, and Helium 2Health News:A 'bionic nose' that knows 2Health News:Consumer Group Releases New Study About Defective Heart Devices and Implants; Patients Arrive in DC Tomorrow 2Health News:Healthcare IT Leaders from InfoLogix Address Gaps in EMR Implementation, Medical Error Reduction and Healthcare Cost Savings at HIMSS09 2
...efficient capture of lifestyle, demographics and c...t-in time saving and error checking devices such a... user definable pop up tables ensuring consistent ...n the pop up tables means that the user simply has...
RLISYS
K-4500
SF-3000
Medicine Products: